New location enhances services for drug development and testing.
- Frontage Europe has relocated its bioanalytical laboratory.
- The move is aimed at enhancing drug development capabilities.
- Expanded services are now available for clients in the pharmaceutical industry.
Frontage Europe has officially relocated its bioanalytical laboratory, aiming to enhance its drug development and testing capabilities. The new facility is designed to better serve clients in the pharmaceutical industry by offering a more comprehensive range of bioanalytical services. This relocation marks a significant step in their commitment to support drug development processes more effectively.
The new bioanalytical laboratory location will enable Frontage Europe to expand its service offerings, including improved methods and technologies for drug testing. This enhancement comes in response to the growing demand for more efficient testing and development solutions in the pharmaceutical sector. By relocating, Frontage Europe seeks to ensure high-quality service for its clients.
This development underscores Frontage Europe's focus on innovation and efficiency in bioanalytical services. The relocation is expected to provide a more conducive environment for research and development activities, ultimately benefiting clients engaged in drug development projects.
